References

1. Relenza® (zanamivir for inhalation) Prescribing Information. GlaxoSmithKline. Research Triangle Park, NC.
2. Centers for Disease Control and Prevention Web Site. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2007 Jul 13;56(RR6):1-42. Available at:
   http://www.cdc.gov/mmwr/PDF/rr/rr5606.pdf. Accessed August 6, 2007.
3. Centers for Disease Control and Prevention Web Site. Influenza (Flu). Preventing the Flu. Antiviral Drugs and Influenza. Available at:
   http://www.cdc.gov/flu/protect/antiviral/. Accessed May 1, 2007.
4. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Influenza pandemic threat: current situation. Preparedness measures. Antivirals drugs: their role during a pandemic. Available at:
   http://www.who.int/csr/disease/avian_influenza/antivirals2005_11_3/en/index.html. Accessed May 1, 2007.
5. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186:1582-8.
6. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254-61.
7. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31-35.
8. Data on File. GlaxoSmithKline. Research Triangle Park, NC.
9. Campion K, Silagy C, Keene O, et al for the MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877-81.
10. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(suppl 1):21-31.
11. Hayden FG, Osterhaus AD, Treanor JJ, et al for the GG187 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med. 1997;337:874-80.
12. Moscana A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-73.
13. Miniño AM, Heron MP, Smith BL. Deaths: Preliminary Data for 2004. National vital statistics reports; vol 54 no 19. Hyattsville, MD: National Center for Health Statistics. 2006.
14. Mäkelä MJ et al. Efficacy and tolerability of the neuraminidase inhibitor zanamivir. J Infect. 2000;40:42-48.